Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03129724` - Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib	N/A
Terminated	`NCT01413607` - The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy	Phase 4
Terminated	`NCT00091611` - Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer	Phase 1
Terminated	`NCT02439008` - Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response	N/A
Completed	`NCT01688999` - Cabozantinib for Advanced Urothelial Cancer	Phase 2
Recruiting	`NCT05184504` - Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
Completed	`NCT04933604` - LPN in Patients With High-complex Renal Tumors
Recruiting	`NCT05068180` - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients	Phase 4
Recruiting	`NCT05119335` - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 1/Phase 2
Terminated	`NCT02543645` - A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer	Phase 1
Terminated	`NCT01712685` - Imaging Studies of Kidney Cancer Using 18F-VM4-037	Phase 2
Terminated	`NCT00816686` - A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer	Phase 1
Completed	`NCT00537056` - Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI	N/A
Completed	`NCT00076011` - Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma	Phase 2
Completed	`NCT00226980` - A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma	Phase 2
Terminated	`NCT02900248` - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting	`NCT03160274` - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Recruiting	`NCT03062410` - Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma	N/A
Completed	`NCT02924922` - Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy	N/A
Terminated	`NCT02386111` - A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma	Phase 1

NCT number	NCT00678392
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 3
Start date	September 3, 2008
Completion date	February 25, 2016

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms